ArticleAntimicrobial agents and chemotherapy2017
Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Effectiveness of conventional antimicrobial agents against carbapenem resistant non-carbapenem β-lactams susceptible Pseudomonas aeruginosa infection in critically ill patients: a multicentre retrospective study.BMC infectious diseases · 2026Observational
- Diagnostic performance of the direct stool Xpert Carba-R assay in active surveillance of carbapenemase-producing enterobacterales.Antimicrobial resistance and infection control · 2025Article
- Antimicrobial activity of cephamycins and β-lactam/β-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula.Scientific reports · 2025Article
- Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections.Journal of biomedical materials research. Part A · 2024Article
- Screening for Antimicrobial Resistance and Genes of Exotoxins inAntibiotics (Basel, Switzerland) · 2023Article
- Epidemiology, Molecular Characteristics, and Virulence Factors of Carbapenem-ResistantInfection and drug resistance · 2022Article
- It's Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Carbapenem-Resistant but Cephalosporin-SusceptibleAntibiotics (Basel, Switzerland) · 2020Article
- Inoculum effect of β-lactam antibiotics.The Journal of antimicrobial chemotherapy · 2019Review
- Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and NonreplicatingACS infectious diseases · 2019Article
- Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.Antimicrobial agents and chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied the resistance mechanism and antimicrobial effects of β-lactams on imipenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.